犬瘟热病毒的静水压灭活

以250MPa的静水压力对犬瘟热病毒（CDV）处理30min之后，CDV被灭活，由其制成的灭活疫苗诱导犬产生中和抗体的能力明显优于传统的福尔马林灭活疫苗，免疫保护率达90％。电镜观察显示，经不同程度静水压力处理后的CDV粒子均发生变形，表面呈现凸起，但CDV H基因部分片段的RT－PCR扩增结果揭示，高达510MPa的静水压力作用30min也未能使其基因片段受到破坏。     

Comparative studies of strains of infectious bovine rhinotracheitis virus isolated from latently infected calves

Three strains (479 C, 778 TL, 982 LE) of infectious bovine rhinotracheitis (IBR) virus isolated from latently infected calves were compared with the prototype strain of IBR virus (LA strain) in studies which included restriction endonuclease analysis, experimental infection, and reciprocal cross protection tests in cattle. From the restriction endonuclease analysis it appeared that the 3 "latent" viruses were derived from the same isolate, and that it differed slightly from the LA strain. However, latency does not seem to have affected the pathogenicity or the immunogenicity of the virus. This is demonstrated by the identical clinical and virologic response of calves subjected to experimental infection with the various strains under study, and by the finding that when the LA strain and a "latent" strain (982 LE) were tested in cross protection tests in cattle, they proved to be mutually protective.     

鸡球虫病免疫学研究进展

鸡球虫病是严重危害养禽业的一种寄生虫病。一直以来,鸡球虫病主要依靠药物来进行防治。但是,随着球虫抗药性问题的日益严重,抗球虫新药开发困难及人们对食品安全的关注,药物在球虫病控制中的作用越来越受到限制,因而用免疫方法来控制鸡球虫病日益受到重视,并有望成为主要的技术手段。目前鸡球虫免疫学研究主要集中在鸡球虫免疫原性、宿主免疫应答及寻找有效的鸡球虫保护性抗原等方面。近年来随着分子生物学和现代生物技术的发展,鸡球虫基因工程疫苗以其独特的优势显示其在未来球虫病控制中的诱人前景,并可能取代传统疫苗而成为鸡球虫病防治的主要手段。     

猪伪狂犬病基因缺失疫苗的制备、安全性、免疫原性、保存期测定及区域试验

为了提供有效的伪狂犬病疫苗，用鸡胚成纤维细胞扩大培养了PrV HB-98突变株（TK^-/gG^-/LacZ^＋），研制了伪狂犬病基因缺失疫苗，并对该疫苗经肌肉接种、经口等免疫途径的最小免疫剂量进行了测定，同时也对4批疫苗的安全性、效力、免疫期和保存期进行了检测；同时将4批疫苗用于免疫23个猪场的母猪、新生仔猪和育肥猪进行区域试验。测定结果表明，疫苗经上述两种途径接种对不同阶段猪的最小免疫剂量均为10^5.0 TCID50；10倍免疫剂量的疫苗对初生仔猪、15日龄仔猪和妊娠母猪是安全的，免疫猪能抵抗强毒的攻击；疫苗在4℃和-20℃下分别可保存6个月和12个月。对伪狂犬病毒抗体阴性的70日龄商品猪和种猪的免疫期为6个月。田间试验表明，4批猪伪狂犬病基因缺失疫苗安全有效，并可用于仔猪发病时的紧急接种。为猪伪狂犬病基因工程疫苗的制备与应用提供了有力的依据。     

表达牛病毒性腹泻病毒E2蛋白的重组乳酸菌的构建及蛋白免疫原性分析

试验旨在构建能表达牛病毒性腹泻病毒（Bovine viral diarrhea virus，BVDV）E2抗原蛋白的重组乳酸乳球菌（Lactococcus lactis），为进一步研制BVDV乳酸菌口服活载体疫苗奠定基础。将BVDV E2基因克隆后测序，根据乳酸乳球菌的密码子偏嗜性进行优化，再将优化的基因片段插入表达载体pNZ8148中，并电转化乳酸乳球菌NZ9000感受态细胞，构建重组乳酸菌pNZ8148-E2/NZ9000，经1 ng/mL乳链菌肽诱导表达后，对菌体物进行了SDS-PAGE和Western blotting分析。将重组乳酸菌pNZ8148-E2/NZ9000口服免疫6~12月龄健康犊牛，在免疫后不同时间点采集血液样品并分离血清，用间接ELISA方法检测抗体水平。结果显示，PCR扩增到了1 149 bp的目的片段，乳酸菌密码子偏嗜性优化后，GC含量从45.28%变为34.30%。重组质粒pNZ8148-E2经酶切鉴定插入片段与预期大小相符，在菌体裂解物中出现大小约42 ku的条带，与预期蛋白大小一致，且该蛋白可与BVDV E2抗体反应。在免疫犊牛的血清中检测到特异性抗BVDV E2蛋白的抗体。本研究结果表明，表达BVDV E2蛋白的重组乳酸菌口服免疫可诱导犊牛产生特异性的体液免疫反应，该重组菌具有较好的免疫原性。     

巨型艾美耳球虫偏菱形样蛋白EmRP免疫原性分析

在前期研究中,从巨型艾美耳球虫(Eimeria maxima)cDNA文库中筛选到了免疫保护性抗原偏菱形样蛋白EmRP,本研究为揭示该抗原的免疫保护机理,进一步检测了其免疫原性。以E.maxima卵囊cDNA为模板,用RT-PCR技术扩增EmRP,并构建真核表达质粒pVAX1-EmRP,将其经腿部肌肉注射2周龄的雏鸡,3周龄加强免疫。分别于首次免疫后和加强免疫后1周,采集血清,用ELISA方法检测血清特异性IgG水平,用荧光定量PCR方法(qPCR)检测细胞因子水平,用流式细胞术检测CD4^+T淋巴细胞和CD8^+T淋巴细胞的比例,分析EmRP诱导的免疫反应。序列分析表明,EmRP含有偏菱形样蛋白超家族成员保守区域,为非跨膜蛋白,分子量约为28.4 kD。真核表达质粒pVAX1-EmRP免疫鸡后,与对照组相比,鸡体IFN-γ、IL-2、IL-10和IL-17等细胞因子转录水平显著提升;CD8^+和CD4^+ T细胞比例显著提高,而血清特异性IgG水平与对照组差异不显著。结果表明,EmRP诱导的免疫保护作用主要是由其诱导的细胞免疫反应实现的,可以作为研制E.maxima新型疫苗的候选抗原。     

Study on Expression and Preliminary Immunocompetence of CIC Protein Containing Molecular Adjuvants

To express CTB-IsdBid-Clfais(CIC) protein and evaluate its immunogenicity, CTB (as a molecular adjuvant) could be tandem linked with IsdBid-Clfais gene by the overlapping PCR method, then CTB-IsdBid-Clfais(CIC) was inserted into pET-32a(+) vector to construct recombinant plasmids pET-32a(+)-CTB-IsdBid-Clfais. The recombinant plasmids pET-32a(+)-CTB-IsdBid-Clfais were transformed into Escherichia coli (E.coli) BL21 to express the CTB-IsdBid-Clfa(CIC) protein, the CIC expression protein and its immune activity were detected by Western blotting and ELISA,respectively. The results showed that the length of CIC gene were 2 072 bp, and CIC was correctly inserted into the pET-32a(+) plasmids, the pET-32a(+)-CTB-IsdBid-Clfais recombinant plasmids were successfully constructed. Western blotting result confirmed that the molecular weight of CIC proteins was 95.9 ku, which were correctly expressed by E.coli BL21 with pET-32a (+)-CTB-IsdBid-Clfais plasmids. ELISA results showed that there was no significant difference among the CIC, IsdBid and Clfais protein groups (P>0.05), and there was extremely significant difference between CIC and BSA protein groups (P<0.01). In conclusion, the pET-32a(+)-CTB-IsdBid-Clfais recombinant plasmids were successfully constructed, CIC proteins were correctly expressed, and were able to react with serum from mice immunized with IsdBid and Clfais,respectively,therefore, CIC proteins had strong immune activity.     

新型鸭呼肠孤病毒DH13株结构蛋白σB的原核表达及免疫原性分析

本研究旨在利用原核表达系统表达新型鸭呼肠孤病毒（NDRV） DH13株重组σB蛋白,并检测其免疫原性,为NDRV基因工程疫苗研制等提供物质材料。采用RT-PCR方法扩增获得NDRV σB基因,构建原核表达重组质粒pET-30a-σB和pET-32a-σB,将2个重组质粒转化大肠杆菌BL21（DE3）感受态细胞,利用IPTG诱导获得相应的重组蛋白,通过SDS-PAGE分析重组蛋白的表达形式。纯化无His的σB蛋白,并以此蛋白作为免疫原免疫新西兰白兔,制备兔源多克隆抗体。利用Ni²⁺柱亲和层析法纯化含His的σB蛋白,以此蛋白作为检测原,通过间接ELISA方法测定兔源多克隆抗体效价;Western blotting鉴定多克隆抗体与重组蛋白的特异性识别能力。结果显示,PCR扩增获得大小约为1 100 bp的σB基因片段。SDS-PAGE结果显示,高效表达出了2种重组σB蛋白,大小分别约为41和46 ku,均以包涵体形式存在。间接ELISA结果显示,制备的多克隆抗体效价达1∶204 800,能特异性地识别原核表达的重组蛋白,表明重组无His的σB蛋白具有良好的免疫原性。Western blotting特异性鉴定结果显示,含His的σB蛋白和无His的σB蛋白均与制备的兔源多克隆抗体发生特异性反应,表明原核表达得到的重组σB蛋白具备良好的反应原性。本试验利用原核表达系统成功地表达出了重组σB蛋白,并证实了重组NDRV σB蛋白具有良好的免疫原性及反应原性,该结果将有助于后续对NDRV σB蛋白生物学功能的鉴定、NDRV诊断用抗原的制备及NDRV新型疫苗的研制。     

Molecular cloning,purification and immunogenicity of recombinant Brucella abortus 544 malate dehydrogenase protein

The Brucella mdh gene was successfully cloned and expressed in E. coli. The purified recombinant malate dehydrogenase protein (rMDH) was reactive to Brucella-positive bovine serum in the early stage, but not reactive in the middle or late stage, and was reactive to Brucella-positive mouse serum in the late stage, but not in the early or middle stage of infection. In addition, rMDH did not react with Brucella-negative bovine or mouse sera. These results suggest that rMDH has the potential for use as a specific antigen in serological diagnosis for early detection of bovine brucellosis.     

转基因植物疫苗研究进展

众多研究表明,病毒的抗原决定簇及细菌毒素亚单位均能在转基因植物中成功表达,并保持良好的免疫原性.与现有的疫苗生产体系相比,植物生产疫苗具有安全、经济、稳定、高效等优势.本文概述了利用不同受体植物生产疫苗的研究现状、免疫原性评价及免疫原基因的优化表达策略.